MedPath

CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision

Not Applicable
Completed
Conditions
Arrhythmia
Tachycardia
Atrial Fibrillation
Ventricular Fibrillation
Registration Number
NCT00402246
Lead Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Brief Summary

The purpose of this study is to determine whether the ability of clinicians to receive and review information from patients implanted with a heart device over the internet (remote care) is comparable to patients who are seen in-office for routine visits to check the status of their device.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2009
Inclusion Criteria
  • Patient will be implanted with a Medtronic Conexus-enabled Cardiac Resynchronization Therapy Defibrillator (CRT-D) or Implantable Cardioverter-Defibrillator (DR-ICD) device.
Exclusion Criteria
  • Patient has permanent rapid beats in the upper chamber of the heart (Atrial Fibrillation) - (constant atrial fibrillation in which pharmacological therapy or cardioversion failed or not attempted).
  • Patient plans to be on chronic warfarin therapy post-implant and is no longer receiving therapies to attempt to control the rhythm of the beats in their atrium.
  • Patient has a previous ICD, CRT-D, Implantable Pulse Generator (IPG) or Cardiac Resynchronization Therapy Pacemaker (CRT-P).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Time Per Patient From a Clinical Event to a Clinical Decision in Response to Arrhythmias, Cardiovascular (CV) Disease Progression, and Device IssuesEnrollment to last visit (up to 15 month post-implant)

Days from device detection of a clinical event to a decision being made in response to the event, as reported by the clinician or as evidenced by device data obtained at interrogation. A clinical event could be any of the following that satisfied pre-specified thresholds: arrhythmias (e.g. at least 12 hours of atrial tachycard/atrial fibrillation in a day), cardiovascular disease progression (e.g. multiple device shocks delivered to terminate a single episode), or device issues (e.g. low battery).

Secondary Outcome Measures
NameTimeMethod
Health Care Utilization (HCU)Enrollment to last visit (up to 15 month post-implant)

Count of HCU visits for each HCU type (cardiovascular (CV) hospitalizations, cardiovascular (CV) emergency department (ED), and cardiovascular (CV) unscheduled clinic office/urgent care visits)

Health Care Utilization: TEEsEnrollment to last visit (up to 15 months post-implant)

Count of Transesophageal echocardiograms (TEEs) performed

Actions Taken for HCU VisitsEnrollment to last visit (up to 15 month post-implant)

Count of HCU visits that involved specific actions taken

Clinically Meaningful AlertsEnrollment to last visit (up to 15 month post-implant)

Count of clinically meaningful alerts as classified by the clinician

Symptomatic AT/AF AlertsEnrollment to last visit (up to 15 month post-implant)

AT/AF represents atrial tachycardia or atrial fibrillation which are arrhythmias involving rapid beating of the atrial chambers of the heart. The devices in this study store how many hours each day that a patient experiences AT/AF. The patient may not be aware they are experiencing these atrial arrhythmias, but if the AT/AF is accompanied by symptoms, the AT/AF is said to be symptomatic AT/AF. Devices in this study have an alert that fires if the patient experiences at least a programmed amount of AT/AF in a day. Measure is count of symptomatic AT/AF alerts as classified by the clinician

AT/AF Alert TreatmentEnrollment to last visit (up to 15 month post-implant)

Count of the treatment (i.e. hospitalization, ED visit, unscheduled clinic office/urgent care visits) in response to the AT/AF alerts

Time Per Patient From a Clinical Event Onset to a Clinical Decision for Symptom-driven Device InterrogationsEnrollment to last visit (up to 15 month post-implant)

Days from a symptom-driven device interrogation event onset to a clinical decision being made in response to the event as reported by the clinician. An event is defined as a subject complaint received by the managing clinician in which the clinician determines that he/she must interrogate the subject's device to properly treat the subject.

Time Per Patient From a Clinical Event Onset to a Clinical Decision for Both Device Events and Symptom-driven Device InterrogationsFrom event onset to clinical decision

Days from device detection of a clinical event or a symptom-driven device interrogation event onset to a clinical decision, as reported by the clinician or as evidenced by device data obtained at interrogation. A clinical event is an event as defined in the primary objective. A symptom-driven device interrogation event is defined as a subject complaint received by the managing clinician in which the clinician determines that he/she must interrogate the subject's device to properly treat the subject.

CareLink Transmission Compliance3, 6, 9, 12 months visits

The CareLink Transmission Compliance Rate for a particular visit (e.g. 3 month visit) is the proportion (ranging from 0 to 1) of subjects with device interrogation data remotely transmitted via the CareLink system on the date it was scheduled to be sent for that visit. The proportion is a fraction in which the denominator is the number of subjects in the Remote Arm who were not exited from the trial prior to the visit of interest, and the numberator is the number of Remote Arm subjects who successfully transmitted device data via the CareLink system on the date it was scheduled to be sent.

Variability in Left Ventricular (LV) Threshold as Measured by Left Ventricular Capture Management (LVCM)1, 3, 6, 9, 12, and 15 months visits

LV Capture Threshold is the required energy(volts) necessary to cause the left ventricule to contract. It is important that a device which paces the left ventricule be set to a threshold such that current conducted through the left ventricular lead will induce contraction in the left ventricle. However, these thresholds may vary over time.

The standard deviation and range (maximum LVCM threshold - minimum LVCM threshold) of the most recent 14 days of LVCM results prior to each follow-up visit were determined for each subject and used to assess within-patient variability in LV thresholds.

State-Anxiety Scale1, 3, 6, 9, 12, and 15 month visit

The State-Anxiety scales for each subject were obtained at multiple time points. The State-Anxiety scale was derived by summing the 20 scores in the State section of the State-Trait Anxiety Inventory (STAI) questionnaire. The State-Anxiety scales can vary from a minimum of 20 (best possible) to a maximum of 80 (worst possible).

Trait-Anxiety Scale1, 3, 6, 9, 12, and 15 months visits

The Trait-Anxiety scales for each subject were obtained at multiple time points. The Trait-Anxiety scale was derived by summing the 20 scores in the Trait section of the STAI questionnaire. The Trait-Anxiety scales can vary from a minimum of 20 (best possible) to a maximum of 80 (worst possible).

Clinic Personnel Satisfaction With Wireless Telemetry (Telemetry + Leadless ECG).After study enrollment has been completed; on average 15.8 months after the center had enrolled its first subject

Following the completion of enrollment in the study, participating clinicians were asked to complete a survey assessing their overall satisfaction with the wireless telemetry feature. Clinicians' rating (1=strongly disagree, 5=strongly agree) of the overall satisfaction with the wireless telemetry feature of the device

In-office Follow-up Burden: Distance Traveled1 month visit

Subjects' responses to the survey. Subjects were asked to provide the distance (in miles) from their home to the clinic/hospital.

In-office Follow-up Burden: Patient Expenses1 month

On a survey at the one month visit, the patient estimated their expenses in traveling to that visit.

In-office Follow-up Burden: Hours Absent From Work Due to Visit1 month

Subjects were asked at their one month visit to indicate on a survey how many hours of work they were missing to attend that visit.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.